Bristol Myers Squibb has drawn coverage from 21 sell-side analysts, resulting in a consensus recommendation of Hold. Breakdown of ratings shows one Sell, thirteen Hold and seven Buy recommendations. Over the past year, analysts have updated their 12-month price targets to an average of $56.86. Notable recent notes include Morgan Stanley reaffirming an Underweight rating while raising its target to $37.00, HSBC maintaining a Hold with a $53.00 objective, and Wall Street Zen upgrading to Strong-Buy in November.

Institutional and hedge fund ownership accounts for 76.41% of outstanding shares. In Q2, Trifecta Capital Advisors and Darwin Wealth Management each established new stakes worth approximately $25,000. REAP Financial Group boosted its position by 202.8%, adding 428 shares to reach 639 shares valued at $30,000. In Q3, Harbor Capital Advisors increased its holding by 107.2% to 605 shares (approximately $27,000), and KERR Financial Planning initiated a position valued near $35,000.

For the quarter ended September 30, Bristol Myers Squibb reported adjusted EPS of $1.63, beating consensus by $0.11, on revenue of $12.22 billion, surpassing Street estimates by $470 million and marking a 2.8% year-over-year increase. Net margin stood at 12.57% with ROE of 76.53%. The company set FY 2025 EPS guidance at a range of $6.40–$6.60. Sell-side forecasts average $6.74 per share for the full year.

The board approved a quarterly dividend of $0.63 per share, payable February 2 to holders of record as of January 2. This represents a 1.6% increase from the prior quarterly payout of $0.62 and an annualized dividend of $2.52, equating to a yield of 4.6%. The payout ratio stands at 85.14%, reflecting management’s commitment to returning capital while balancing reinvestment in late-stage oncology and immunology pipelines.